SEC 13F Intelligence

Managers / Q4 2019 · view latest →

Centerbridge Partners, L.P.

CIK 0001484836 · 375 PARK AVENUE, 11TH FLOOR, NEW YORK, NY, 10152 · 212 672 5000

Reported Value
$618M
Q4 2019
Positions
17
Filings on Record
33
2019–present window
Filed
Feb 14, 2020
original filing

Summary

Centerbridge Partners, L.P. reported $618M in U.S.-listed holdings across 17 positions for Q4 2019.

The portfolio is heavily concentrated: American Renal Associates Ho alone accounts for 29.6% of reported value.

Compared with Q3 2019, the fund opened 1 new position and exited 3.

Portfolio Metrics

Turnover
+7.3%
vs prior filed quarter
Largest Position
+29.6%
American Renal Associates Ho
New / Exited
1 / 3
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $982MQ4 ’18Q1 ’19: $729MQ2 ’19: $815MQ3 ’19: $550MQ4 ’19: $618MQ4 ’19Q1 ’20: $412MQ2 ’20: $468MQ3 ’20: $894MQ4 ’20: $1.2BQ4 ’20Q1 ’21: $1.1BQ2 ’21: $1.1BQ3 ’21: $856MQ4 ’21: $1.8BQ4 ’21Q1 ’22: $1.6BQ2 ’22: $1.1BQ3 ’22: $875MQ4 ’22: $1.0BQ4 ’22Q1 ’23: $1.0BQ2 ’23: $642MQ3 ’23: $467MQ4 ’23: $604MQ4 ’23Q1 ’24: $623MQ2 ’24: $505MQ3 ’24: $478MQ4 ’24: $468MQ4 ’24Q1 ’25: $510MQ2 ’25: $434MQ3 ’25: $101MQ4 ’25: $59MQ4 ’25Q1 ’26: $61Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 90.2%US DOMESTIC: 8.1%ADR: 1.4%Other: 0.4%
  • Common Stock · 90.2% · $557M
  • US DOMESTIC · 8.1% · $50M
  • ADR · 1.4% · $8M
  • Other · 0.4% · $2M

Quarter-over-Quarter Changes full breakdown →

vs Q3 2019 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
REALOGY HLDGS CORPNEW+235.0K235.0K+$2M$2M
INTELSAT S ASOLD OUT−1.07M0−$24M$0
SEADRILL LTDSOLD OUT−4.04M0−$8M$0
IRSA INVERSIONES Y REP S ASOLD OUT−256.2K0−$1M$0
TEVATEVA PHARMACEUTICAL INDS LTDTRIMMED−962.5K852.4K−$4M$8M
PCGPG&E CORPTRIMMED−1.09M7.74M−$4M$84M
ENSCO JERSEY FIN LTDADDED+6.01M70.58M+$6M$50M
AMERICAN RENAL ASSOCIATES HOHELD+017.62M+$71M$183M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2019

7 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1AMERICAN RENAL ASSOCIATES HOCOM29.57%$183M17.62M
2HGVHILTON GRAND VACATIONS INChistory →COM22.83%$141M4.10M
3GNKGENCO SHIPPING & TRADING LTDhistory →SHS18.03%$111M10.49M
4PCGPG&E CORPhistory →COM13.62%$84M7.74M
5ENSCO JERSEY FIN LTDNOTE 3.000% 1/38.11%$50M70.58M
6FOCUS FINL PARTNERS INCCOM CL A4.30%$27M901.8K
7REALOGY HLDGS CORPCOM0.37%$2M235.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$61M3May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$59M2Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$101M4Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$434M9Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$510M11May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$468M13Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$478M15Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$505M17Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$623M20May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$604M20Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$467M25Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$642M27Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$1.0B29May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$1.0B34Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$875M62Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$1.1B67Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$1.6B71May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$1.8B111Feb 17, 2022RESTATEMENTchanges · EDGAR ↗
Q3 2021$856M108Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$1.1B124Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$1.1B109May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$1.2B36Feb 23, 2021RESTATEMENTchanges · EDGAR ↗
Q3 2020$894M23Nov 17, 202013F-HRchanges · EDGAR ↗
Q2 2020$468M33Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$412M40May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$618M17Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$550M22Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$815M20Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$729M26May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$982M37Feb 14, 201913F-HRchanges · EDGAR ↗

Other Included Managers

This filing reports holdings on behalf of 9 additional managers.

  • Centerbridge Credit Advisors, L.L.C.028-13862
  • Centerbridge Partners Holdings, LLC028-13861
  • Aronson Jeffrey028-13858
  • Gallogly Mark T028-13857
  • Centerbridge Special Credit Advisors, L.L.C.028-14395
  • Centerbridge Advisors, LLC028-15424
  • Centerbridge Special Credit Advisors II, L.L.C028-16779
  • Centerbridge Special Credit Advisors III, L.L.C.028-19382
  • Centerbridge Advisors II, LLC

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.